Washington – The Food and Drug Administration (FDA) has given approval for the zuranolone, sold under the brand name Zurzuvae, to be used as a pill to treat postnatal depression as alternative to intravenous injection. The drug can be taken by patients as a once-daily pill for two weeks and, per drug manufacturers Sage Therapeutics and Biogen’s direction. The pill will be available later this year.